Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis

被引:20
|
作者
Hoedemaekers, A
Bessereau, JL
Graus, Y
Guyon, T
Changeux, JP
Berrih-Aknin, S
Vriesman, PV
De Baets, MH
机构
[1] Maastricht Univ, Dept Neurol, NL-6202 AZ Maastricht, Netherlands
[2] Univ Limburg, Dept Immunol, NL-6200 MD Maastricht, Netherlands
[3] Inst Pasteur, CNRS, UAD 1284, Unite Neurobiol Mol, F-75724 Paris, France
[4] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
[5] Hop Marie Lannelongue, CNRS, URA 1159, F-92350 Le Plessis Robinson, France
关键词
experimental autoimmune myasthenia gravis; acetylcholine receptor; autoimmunity;
D O I
10.1016/S0165-5728(98)00126-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Injection of anti-AChR antibodies in passive transfer experimental autoimmune myasthenia gravis (EAMG) results in increased degradation of acetylcholine receptor (AChR) and increased synthesis of AChR alpha-subunit mRNA. Passive transfer of anti-Main Immunogenic Region (MIR) mAb 35 in aged rats does not induce clinical signs of disease nor AChR loss. The expression of the AChR subunit genes was analyzed in susceptible and resistant rats. In aged EAMG resistant rats, no increase in the amount of AChR alpha-subunit mRNA was measured. In vivo AChR degradation experiments did not show any increase in AChR degradation rates in aged resistant rats, in contrast to young susceptible rats. Taken together, these data demonstrate that resistance of the AChR protein to antibody-mediated degradation is the primary mechanism that accounts for the resistance to passive transfer EAMG in aged rats. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 50 条
  • [21] Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis
    Im, SH
    Barchan, D
    Souroujon, MC
    Fuchs, S
    JOURNAL OF IMMUNOLOGY, 2000, 165 (07): : 3599 - 3605
  • [22] EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS (EAMG) IN MICE - ROLE OF IA MOLECULE
    CHRISTADOSS, P
    KRCO, CJ
    LENNON, VA
    LAMBERT, EH
    DAVID, CS
    FEDERATION PROCEEDINGS, 1981, 40 (03) : 971 - 971
  • [23] The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ
    Weiss, J. -M.
    Cufi, P.
    Le Panse, R.
    Berrih-Aknin, S.
    REVUE NEUROLOGIQUE, 2013, 169 (8-9) : 640 - 649
  • [24] EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS AND MYASTHENIA-GRAVIS - COMPARISON OF THE IMMUNOLOGICAL RESULTS OBTAINED
    GEFFARD, M
    SOUAN, ML
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 505 : 712 - 714
  • [25] CYTOKINE DIFFERENTIATION IN RELATION TO HUMAN MYASTHENIA-GRAVIS AND EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    LINK, H
    WANG, ZY
    OLSSON, T
    NEUROLOGY, 1994, 44 (04) : A189 - A189
  • [26] Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis
    Luo, Jie
    Lindstrom, Jon
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2018, 1413 (01) : 76 - 81
  • [27] Autoimmune myasthenia gravis
    Gilhus, Nils Erik
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (03) : 351 - 358
  • [28] ICOS is essential for the development of experimental autoimmune myasthenia gravis
    Scott, BG
    Yang, HA
    Tüzün, E
    Dong, C
    Flavell, RA
    Christadoss, P
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 153 (1-2) : 16 - 25
  • [29] Bortezomib as a novel treatment for experimental autoimmune myasthenia gravis
    Alejandro, Gomez
    Kathleen, Vrolix
    Marko, Phernambucq
    Pilar, Martinez-Martinez
    De Baets, Marc H.
    Mario, Losen
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 88 - 89
  • [30] STEROID TREATMENT FOR EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    BARONE, DA
    LAMBERT, DH
    POSER, CM
    ARCHIVES OF NEUROLOGY, 1980, 37 (10) : 663 - 666